Business Wire

The Reasons Why Milan is the Best Choice for the European Medicines Agency

Jaa

“With one of Europe’s best research and business environment, excellent links with Europe and the world, a vibrant and globally renowned lifestyle, as well as superb conditions for a smooth and effective relocation, Milan is ready to host the European Medicines Agency (EMA)” stated Prof. Silvio Garattini, eminent scientist and Director of the Mario Negri Institute for Pharmacological Research in Milan, an authoritative foundation dedicated to world-class clinical and biomedical research.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170824005820/en/

View of the Pirelli Building in downtown Milan (Photo: Explora Tourism).

View of the Pirelli Building in downtown Milan (Photo: Explora Tourism).

Seven reasons demonstrate why Milan represents the ideal setting to ensure the continuity of EMA's operations during the post-Brexit transition and offers the opportunity for a fulfilling personal and professional life:

1) A Smooth Relocation - The EMA will be hosted in a superbly located, ready-to-use state-owned building, the “Pirelli Building”. To foster retention, the EMA staff will be assisted in the transition by a newly established and fully dedicated Support Centre. Over 250 air connections per week with London will facilitate the transitional phase for staff needing to commute.

2) Europe at Your Fingertips - Three major airports (MPX, LIN, BGY) serve Milan with nearly 1,300 weekly flights to 27 EU capitals. A highly-developed rail and highway network connects the city to all other major Italian centres, to numerous globally renowned touristic destinations and to Italy’s neighboring countries.

3) The Best Hospitality - With nearly 100,000 beds and 17,400 restaurants and bars, Milan provides a wide range of accommodation and catering choices, very recently strengthened thanks to EXPO 2015. Located in the city center, the new EMA headquarters would have excellent access to a wide range of facilities.

4) Science and Innovation - A comprehensive network of international schools, eighteen universities and art academies will be available to those who relocate, together with an extensive network of public and private research institutions which create a vibrant environment for research and innovation. Italy has the second largest pharmaceutical industry in Europe in terms of production volumes, 60% of which are in Milan’s metropolitan area, and is the world’s largest exporter of medicines per capita.

5) EU Sinergy - The Joint Research Centre (JRC), the European Commission’s science and knowledge Directorate General, is based in Ispra, approximately 50km North of Milan, and the European Food Safety Authority (EFSA) is based in Parma, 120km South-East of the city. This creates the potential for three EU science and research bodies to be based within 200km of each other, providing ample opportunities for an effective collaboration.

6) Italian Lifestyle - Quality of life in Milan is among the very best in the world, with abundant high-quality housing at competitive prices, a state-of-the-art health system, a thriving artistic and cultural environment, a unique food scene, and an efficient public transport system including car and bike sharing schemes. Everything is in reach: the beauty of the Italian coastline, the charm of Italy’s lakes and the wonders of the highest mountains in Europe.

7) Career Opportunities - Milan is a leader in financial and banking services, engineering, communication, manufacturing, energy, and basic and applied research. The city also plays an unrivalled role in the design and fashion industry. Nearly 3,600 multinational companies, with 280,000 employees and a yearly turnover of €167 billion, have chosen Milan as their base to manage their operations in Italy, Europe and globally.

Fondazione Milano per EXPO
The Foundation is a no-profit organization operating since 2008 which contributed to the success of EXPO 2015, both in the bidding phase and during the universal exposition in Milan (May 1st - October 31st, 2015). Created by Assolombarda (the Lombardy regional association of entrepreneurs), the Metropolitan Chamber of Commerce of Milan, Monza and Brianza and Lodi, and a group of entrepreneurs, the Foundation promotes international cooperation models featuring a high degree of social responsibility.

Visit our website: http://emamilano.eu
Watch our video: https://youtu.be/HEjkDgglslg
Visit the Fondazione website: www.fondazionemilanoperexpo2015.it

Contact information

Press contact Fondazione Milano:
Matteo Martone
APCO Worldwide
emamilano@apcoworldwide.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme tältä julkaisijalta, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Ipsen Receives Approval from European Commission for Xermelo® (Telotristat Ethyl) for the Treatment of Carcinoid Syndrome Diarrhea in Patients Inadequately Controlled by Somatostatin Analogue Therapy19.9.2017 19:00Tiedote

Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical group, today announced that the European Commission has approved Xermelo® (telotristat ethyl) 250 mg three times a day (tid) for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analogue (SSA) therapy in adults inadequately controlled by SSA therapy. This approval allows for the marketing of Xermelo® (telotristat ethyl) in the above indication in all 28 member states of the European Union, Norway and Iceland. David Meek, Chief Executive Officer, Ipsen stated: “We are delighted to provide patients suffering from inadequately controlled carcinoid syndrome with a new treatment option in combination with a somatostatin analogue that demonstrates both efficacy and safety in particularly improving diarrhea, a most debilitating symptom. Xe

6th Annual World Patient Safety, Science & Technology Summit to Be Held in London, England19.9.2017 18:00Tiedote

The Patient Safety Movement Foundation (PSMF) announces that the 6th Annual World Patient Safety, Science & Technology Summit will take place in London on February 23-25, 2018. Rt. Hon. Jeremy Hunt MP, the Secretary of State for Health from England’s Department of Health, invited PSMF to hold its 6th annual Summit in London during his speech at the Summit in February of this year. This is the first time the Summit will be held outside of the United States. Over the years, the PSMF has taken an increasingly international scope to reach zero preventable patient deaths by 2020. They currently have over 30 Regional Chapters around the world and partnerships with global organizations such as the World Federation of Societies of Anaesthesiologists (WFSA), European Society of Anaesthesiology (ESA), Global Sepsis Alliance (GSA), the Taiwan Patient Safety Culture Club, Sistema Españo

Vertex Announces Upcoming Presentations of Data at 2017 North American Cystic Fibrosis Conference19.9.2017 17:50Tiedote

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that 11 abstracts from its cystic fibrosis (CF) research and development program will be presented at the annual North American Cystic Fibrosis Conference (NACFC) in Indianapolis, November 2 to 4, 2017. Previously announced data from the Phase 3 EVOLVE and EXPAND studies of the investigational tezacaftor/ivacaftor combination in people with CF ages 12 and older who have certain mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene will be presented for the first time. Additionally, data from the Phase 3 extension study of ORKAMBI® (lumacaftor/ivacaftor) in children with CF ages 6 to 11 who have two copies of the F508del mutation and real-world KALYDECO® (ivacaftor) data will be presented. The company also submitted an abstract for the late-breaking poster session with previously announced Phase 1

Biker Summer 2017 campaign: Last Chance to Win Great Prizes from Moto-tyres.co.uk19.9.2017 16:57Tiedote

Moto-tyres.co.uk wants to know: For the fifth year in a row, the online motorbike shop is asking bikers from ten European countries about their Biker Summer 2017 travel plans, favourite destinations and longest tours. For survey participants, Moto-tyres.co.uk and its sister shops in other European countries are raffling prizes to get every biker’s heart beating faster, including vouchers for new motorbike tyres, a GARMIN motorbike GPS navigation system, and a GoPro camera with helmet attachment. For more information and a link to the survey, go to: www.moto-tyres.co.uk/promotion-biker-summer-2017.html. The Biker Summer 2017 campaign is running until 30th September 2017 – so you still have time to join in and win top-quality equipment for your next bike tour. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170919006105/en/

Andersen Global Expands into Uruguay19.9.2017 16:30Tiedote

Andersen Global announces its expansion into Uruguay through a Collaboration Agreement with Fischer & Schickendantz, one of the country’s leading law firms. The addition of Fischer & Schickendantz continues Andersen Global’s expansion and robust presence within the Latin American region. The team is led by Managing Partner, Juan Federico Fischer. “The addition of Juan Federico and the individuals at Fischer & Schickendantz bring a new depth to our team and our business development efforts in South America, while allowing us to deliver additional services in the region,” said Andersen Tax CEO, Mark Vorsatz. “Uruguay is the next major step in our firm’s growth and is an excellent complement for Andersen Global. The ability to provide a full scope of services in Uruguay offers significant advantages, especially given their large cross border client base and Uruguay’s increase

Horizon Petroleum Enters into Definitive Agreements to Acquire Concessions in Poland19.9.2017 16:05Tiedote

Horizon Petroleum Ltd. (the “Company” or “Horizon”) (TSXV:HPL) is pleased to report that further to its press releases dated June 23, 2017, and July 26, 2017, it has entered into a series of definitive agreements (the “Agreements”) with Dublin-based San Leon Energy plc (“SLE”) regarding the purchase from wholly-owned subsidiaries of SLE and other SLE-controlled entities, of 100% interests in 2 oil & gas concessions in the Republic of Poland known as Cieszyn and Bielsko-Biala (the “Primary Concessions”), plus 100% working interests in 2 additional oil & gas concessions in Poland known as Prusice and Kotlarka, and another concession which is under application (together the “Secondary Concessions”). These concessions cover 3,030km2 and lie within the prolific Rotliegendes Basin and Carpathian Foldbelt, where Horizon intends to target undeveloped conventional natural gas discoveries. Gas infr

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme